Durable Responses and Survival in High-risk Myelodysplastic Syndrome and Acute Myeloid Leukemia Patients Receiving the Allogeneic Leukemia-derived Dendritic Cell Vaccine DCP-001

Hemasphere. 2023 Nov 2;7(11):e968. doi: 10.1097/HS9.0000000000000968. eCollection 2023 Nov.

Authors

Luca L G Janssen^{1

2}, Theresia M Westers^{1

2}, Jeroen Rovers³, Peter J M Valk⁴, Jacqueline Cloos^{1

2}, Tanja D de Gruijl^{2

5}, Arjan A van de Loosdrecht^{1

2}

Affiliations

¹ Amsterdam UMC, Vrije Universiteit, Department of Hematology, Amsterdam, The Netherlands.
² Cancer Center Amsterdam, Cancer Biology and Immunology, Amsterdam, The Netherlands.
³ Mendus AB, R&D Center, Leiden, The Netherlands.
⁴ Erasmus University Medical Center, Department of Hematology, Rotterdam, The Netherlands.
⁵ Amsterdam UMC, Vrije Universiteit, Department of Medical Oncology, Amsterdam, The Netherlands.

No abstract available